Our Publications (TCSL and historical PDCS)

(Laboratory or alumni authors in bold)

2021 (Eleven publications)

Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L,Guedan S, Alexander KA, Zhang Z, Rommel PC, Singh N, Glastad KM, Richardson MW, Watanabe K, Tanyi JL, O'Hara MH, Ruella M, Lacey SF,Moon EK, Schuster SJ, Albelda SM, Lanier LL, Young RM, Berger SL, June CH. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell. PMID: 34861191. https://doi.org/10.1016/j.cell.2021.11.016

Manjunath SH, Cohen AD, Lacey SF, Davis MM, Garfall AL, Melenhorst JJ, Maxwell R, Arscott WT, Maity A, Jones JA, Plastaras JP, Stadtmauer EA, Levine BL, June CH, Milone MC, and Paydar I. 2021. The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research. 2021 Sep 15:clincanres.0308.2021. https://doi.org/10.1158/1078-0432.CCR-21-0308

Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, Ruella M, Bhattacharyya S, Wherry EJ, and Schuster SJ. 2021. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood 2021 Sep 9:blood.2021012634. https://doi.org/10.1182/blood.2021012634

Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T,DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, Reich TJ, Bhoj VG, Haines KM, Maus MV, Melenhorst JJ, Young RM, Jadlowsky JK, Marcucci KT, Bradner JE, Levine BL, Porter DL, Bushman FD, Kohli RM, June CH, Davis MM, Lacey SF, Vahedi G, and Fraietta JA. 2021. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia Journal of Clinical Investigation. 2021 Aug 16;131(16):e145459. https://doi.org/10.1172/JCI145459

Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, and Maude SL. 2021. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia Journal of Clinical Oncology. 2021 June 22. JCO2003458 doi: 10.1200/JCO.20.03458. https://doi.org/10.1200/JCO.20.03458

Durgin JS, Henderson F Jr, Nasrallah MP, Mohan S, Wang S, Lacey SF, Melenhorst JJ, Desai AS, Lee JYK, Maus MV, June CH, Brem S, O'Connor RS, Binder Z, and O'Rourke DM. 2021. Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma Frontiers in Oncology. 2021 May 7;11:669071. https://doi.org/10.3389/fonc.2021.669071

Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, Lacey SF, Roy NH, Burkhardt JK, Colomb F, Damra M, Abdel-Mohsen M, Liu T, Liu D, Standley DM, Young RM, Brogdon JL, Grupp SA, June CH, Maude SL, Gill S, and Ruella M. 2021. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nature Medicine. 2021 April 22. doi: 10.1038/s41591-021-01326-5. https://doi.org/10.1038/s41591-021-01326-5

Bernabei L, Tian L, Garfall AL, Melenhorst JJ, Lacey SF, Stadtmauer EA, Vogl DT, Gonzalez VE, Plesa G, Young RM, Waxman A, Levine BL, June CH, Milone MC, Cohen AD.2021. B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. British Journal of Haematology. 2021 Mar 13. doi: 10.1111/bjh.17397. https://doi.org/10.1111/bjh.17397

Chong EA, Ruella M, Schuster SJ; Lymphoma Program Investigators at the University of Pennsylvania. 2021. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. New England Journal of Medicine. 2021 Feb 18;384(7):673-674. doi: 10.1056/NEJMc2030164. https://doi.org/10.1056/NEJMc2030164

Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan A, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, and Riley JL. 2021. CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication. Journal of Clinical Investigation. 2021 Feb 11:144486. doi: 10.1172/JCI144486. https://doi.org/0.10.1172/JCI144486

Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, Barz Leahy A, Callahan C, Dolan JG, Fitzgerald JC, Gladney W, Lacey SF,Liu H, Maude SL, McGuire R, Motley LS, Teachey DT, Wertheim GB, Wray L, DiNofia AM, and Grupp SA. 2021. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial Journal of Clinical Oncology. 2021 Jan 8:JCO2002477. 0.1200/JCO.20.02477 https://doi.org/0.1200/JCO.20.02477

2020 (Eleven publications)

Whitney JE, Feng R, Koterba N, Chen F, Bush J, Graham K, Lacey SF, Melenhorst JJ, Parikh SM, Weiss SL, Yehya N. 2020. Endothelial Biomarkers Are Associated With Indirect Lung Injury in Sepsis-Associated Pediatric Acute Respiratory Distress Syndrome. Critical Care Explorations. 2020 Dec 4;2(12):e0295. doi: 10.1097/CCE.0000000000000295. eCollection 2020 Dec. https://doi.org/10.1097/CCE.0000000000000295

Jacobson JM, Jadlowsky JK, Lacey SF, Fraietta JA, Plesa G, Chono H, Lee DH, Kulikovskaya I, Bartoszek C, Chen F, Tian, Dimitri A, Levine BL, Veloso EA, Hwang WT, and June CH. 2020. Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. Molecular Therapy. 2020 Nov 11:S1525-0016(20)30605-5. doi: 10.1016/j.ymthe.2020.11.007. https://doi.org/10.1016/j.ymthe.2020.11.007

Diorio C, Shaw PA, Pequignot E, Orlenko A, Chen F, Aplenc R, Barrett DM, Bassiri H, Behrens E, DiNofia AM, Gonzalez V, Koterba N, Levine BL, Maude SL, Meyer NJ, Moore JH, Paessler M, Porter DL, Bush JL, Siegel DL, Davis MM, Zhang D, June CH, Grupp SA, Melenhorst JJ, Lacey SF, Weiss SL, and Teachey DT. 2020. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Adv. 2020 Oct 27;4(20):5174-5183. doi: 10.1182/bloodadvances.2020002592. https://doi.org/10.1182/bloodadvances.2020002592

Zhang Z, Schuster SJ, Lacey SF, Milone MC, Monos D, and Bhoj VG. 2020. Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source. Blood Adv. 2020 Sep 22;4(18):4292-4295. doi: 10.1182/bloodadvances.2020002435. https://doi.org/10.1182/bloodadvances.2020002435

Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. Molecular Therapy 2020 Nov 4;28(11):2367-2378. doi: 10.1016/j.ymthe.2020.07.017. Epub 2020 Jul 21. https://doi.org/10.1016/j.ymthe.2020.07.017

Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, Alanio C, Kuri-Cervantes L, Pampena MB, D'Andrea K, Manne S, Chen Z, Huang YJ, Reilly JP, Weisman AR, Ittner CAG, Kuthuru O, Dougherty J, Nzingha K, Han N, Kim J, Pattekar A, Goodwin EC, Anderson EM, Weirick ME, Gouma S, Arevalo CP, Bolton MJ, Chen F, Lacey SF, Ramage H, Cherry S, Hensley SE, Apostolidis SA, Huang AC, Vella LA; UPenn COVID Processing Unit, Betts MR, Meyer NJ, and Wherry EJ. 2020. Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions. 2020. Science. 2020 Sep 4;369(6508):eabc8511. doi: 10.1126/science.abc8511. Preprint. https://doi.org/10.1126/science.abc8511

Lacey SFand Fraietta JA. 2020. First Trial of CRISPR-Edited T cells in Lung Cancer. Trends Mol Med.Jun 12:S1471-4914(20)30149-0. https://doi.org/10.1016/j.molmed.2020.06.001

Zhang Q, Orlando E, Wang H, Bogusz AM, Liu X, Lacey SF,Strauser HT, Nunez-Cruz S, Nejati R, Zhang P, Brooks S, Watt C, Melenhorst JJ, June CH, Schuster SJ, and Wasik MA. 2020. Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of epigenome. BloodJun 9:blood.2020005123. https://doi.org/10.1182/blood.2020005123

Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL, Lacey SF, Melenhorst JJ, Veloso E, Gaymon A, Pequignot E, Shan X, Hwang WT, June CH, and Porter DL. 2020. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology2020 Apr 16:JCO1903237. doi: 10.1200/JCO.19.03237 https://doi.org/10.1200/JCO.19.03237

Whitney JE, Zhang B, Koterba N, Chen F,Bush J, Graham K, Lacey SF,Melenhorst JJ,Teachey DT, Mensinger JL, Yehya N, and Weiss SL. 2020. Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis. Critical Care Medicine2020 Mar;48(3):344-352. https://doi.org/10.1097/CCM.0000000000004091

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF,and June CH. 2020. CRISPR-engineered T cells in patients with refractory cancer. Science2020 Feb 6. pii: eaba7365. https://doi.org/10.1126/science.aba7365

2019 (Eight publications)

Panjwani MK, Atherton MJ, MaloneyHuss MA, Haran KP, Xiong A, Gupta M, Kulikovskaya I, Lacey SF, and Mason NJ 2019. Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. Oncoimmunology, 2019 Oct 23;9(1):1676615. https://doi.org/1080/2162402X.2019.1676615

Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, and Bushman FD. 2019. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. Journal of Clinical Investigation, 2019 Dec 17. pii: 130144. https://doi.org/10.1172/JCI130144

Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, and Porter DL. 2019. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2019Dec9:JCO1901892. https://ascopubs.org/doi/abs/10.1200/JCO.19.018921859

Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, and Gill S. 2019. A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells. Blood , Nov 8th. pii: blood.2019001859. https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019001859

Cohen AD, Garfall AL, Dogan A, Lacey SF, Martin C, Lendvai N, Vogl DT, Spear M, and Lesokhin AM. 2019. Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. Blood Advances, Aug 27th. 3(16): 2487-2490. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712532/

Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, and Beatty GL. 2019. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Molecular Therapy, Jul 30. pii: S1525-0016(19)30328-4. https://www.sciencedirect.com/science/article/pii/S1525001619303284?via%3Dihub

Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, and Milone MC. 2019. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. Journal of Clinical Investigation, Mar 21;130. pii: 126397. https://www.jci.org/articles/view/126397

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, and June CH. 2019. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Journal of Clinical Investigation Insight, Feb 21;4(4). pii: 127684 https://insight.jci.org/articles/view/127684

2018 (Fifteen publications)

Chen F, Fraietta JA, June CH, Xu Z, Melenhorst JJ, and Lacey SF. 2018. Engineered T Cell Therapies from a Drug Development Viewpoint. Engineering, Dec 31th. doi: 10.1016/j.eng.2018.11.010 https://doi.org/10.1016/j.eng.2018.11.010

Long KB, Young RM, Boesteanu AC, Davis MM, Melenhorst JJ, Lacey SF, DeGaramo DA, Levine BL, and Fraietta JA. 2018. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. Frontiers in Immunology, Dec 3rd. doi: 110.3389/fimmu.2018.02740 https://doi.org/10.3389/fimmu.2018.02740

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, and Melenhorst JJ. 2018. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine, Oct 1st. doi: 10.1038/s41591-018-0201-9 https://doi.org/10.1002/ana.25315

Gofshteyn JS, Shaw PA, Teachey DT, Grupp S, Maude S, Banwell B, Chen F, Lacey SF, Melenhorst JJ, Edmonson MJ, Panzer J, Barrett DM, and McGuire J. 2018. Neurotoxicity after CTL019 in a Pediatric and Young Adult Cohort. Annals of Neurology, Sep 3. doi: 10.1002/ana.25315. https://doi.org/10.1002/ana.25315

Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA, George SM, Stelekati E, Chen F, Melenhorst JJ, Lacey SF, Xu X, Wherry EJ, Gangadhar TC, Amaravadi RK, Schuchter LM, and Vonderheide RH. 2018. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. OncoImmunology, 7:10, DOI: 10.1080/2162402X.2018.1468956. https://doi.org/10.1080/2162402X.2018.1468956

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, and Milone MC. 2018. Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells. Cancer immunology Research, July 20th. https://doi.org/10.1158/2326-6066.CIR-17-0405

Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, and Schuster SJ. 2018. Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma. Blood, June 20th. https://doi.org/10.1182/blood-2018-03-837609

Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, and Melenhorst JJ. 2018. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, May 30th. https://doi.org/10.1038/s41586-018-0178-z

Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH. 2018. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Molecular Therapy, May 8th. https://doi.org/10.1016/j.ymthe.2018.05.003

Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu, AC, Wang Y, O’Connor RS, Hwang WT, Pequignot E, Ambrose D, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young, RM, Johnson FB, Kulikovskaya I, Liu, Li, Xu Jun, Kassim, SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, and Melenhorst JJ. 2018. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia Nature Medicine, April 30th. https://doi.org/10.1038/s41591-018-0010-1

Kong, W, Lacey SF, Melenhorst JJ, and Fraietta JA. 2018. Biomarkers in Chimeric Antigen Receptor T-cell Therapy. Biomarkers in Medicine, April 26th. https://doi.org/10.2217/bmm-2018-0054

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, and June CH. 2018. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight, April 19th. 10.1172/jci.insight.120505 https://doi.org/10.1172/jci.insight.120505

Xu J, Melenhorst JJ, and Fraietta JA. 2018. Toward precision manufacturing of immunogene T-cell therapies. Cytotherapy, April 10th. pii: S1465-3249(17)30783-1. https://doi.org/10.1016/j.jcyt.2017.12.007

Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, and June CH. 2018. Activity of Mesothelin-specific Chimeric Antigen Receptor T cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology, Mar 19. pii: S0016-5085(18)30323-8. https://www.sciencedirect.com/science/article/pii/S0016508518303238?via%3Dihub

Guedan S, Posey AD, Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, Young RM and June CH. 2018. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight, January 11. doi 10.1172/jci.insight.96976. https://doi.org/10.1172/jci.insight.96976

2017 (Ten publications)

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, and June CH. 2017. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. New England journal of Medicine, December 10. doi 10.1056/NEJMoa1708566. https://doi.org/10.1056/NEJMoa1708566

Also see Editorial: 'A Milestone for CAR T Cells' Tran et al. http://www.nejm.org/doi/full/10.1056/NEJMe1714680

Marcucci KT, Jadlowsky JK, Hwang WT, Suhoski-Davis M, Gonzalez VE, Kulikovskaya I, Gupta M, Lacey SF, Plesa G, Chew A, Melenhorst JJ, Levine BL, and June CH. 2017. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Molecular Therapy ,Oct 20. pii: S1525-0016(17)30528-2. https://doi.org/10.1016/j.ymthe.2017.10.012

Jennifer L. Hope, Christopher J. Stairiker, Panagiota I. Spantidea, Donald T. Gracias, Alison J. Carey, Adam J. Fike, Marjan van Meurs, Inge Brouwers-Haspels, Laurine C. Rijsbergen, Joseph A. Fraietta, Yvonne M. Mueller, Rosemarieke C. Klop1, Erietta Stelekati, E. John Wherry, Stefan J. Erkeland and Peter D. Katsikis. 2017. The Transcription Factor T-Bet Is Regulated by MicroRNA-155 in Murine Anti-Viral CD8+ T Cells via SHIP-1 Frontiers in Immunology, 06 December 2017. https://doi.org/10.3389/fimmu.2017.01696

Lorena Loarca, Joseph A. Fraietta, Vanessa Pirrone, Zsofia Szep and Brian Wigdahl. Human Immunodeficiency Virus (HIV) Infection and Cancer in "HIV/AIDS - Contemporary Challenges", book edited by Nancy Dumais, ISBN 978-953-51-2962-2, Print ISBN 978-953-51-2961-5 Published: February 22, 2017.


Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey A, Williams AD, So A, Conejo-Garcia JR, Plesa G, Young RM, McGettigan S, Campbell J, Pierce RH, Matro JM, DeMichele AM, Clark AS, Cooper LJN, Schuchter LM, Vonderheide RH, and June CH. 2017. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunology Research, 2017 Nov 6. pii: canimm.0189.2017.


Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, Melenhorst JJ, and Wasik MA. 2017. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy; clinicopathological insights. Blood, 2017 Oct 26. pii: blood-2017-08-802413.


Leibman RS, Richardson MW, Ellebrecht CT, Maldini CR, Glover JA, Secreto AJ, Kulikovskaya I, Lacey SF, Akkina SR, Yi Y, Shaheen F, Wang J, Dufendach KA, Holmes MC, Collman RG, Payne AS, and Riley JL. 2017. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathogens, 2017 Oct 12;13(10):e1006613.


Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, Waldron E, Chakraborty A, Awasthi R, Levine BL, Melenhorst JJ, Grupp SA, June CH, and Lacey SF. 2017. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood, 2017. 130: 2317-2325. (Associated commentary: 'Road trip to remission with CARs' by Samantha M. Jaglowski. Blood 2017 130:2240; doi: https://doi.org/10.1182/blood-2017-10-80858. Link)


O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot J-M, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV 2017. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine, July 19th. Vol 9, Issue 399


Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, and Byrd JC. 2017. Ibrutinib treatment improves T cell number and function in CLL patients. Journal of Clinical Investigation, July 17th. pii: 89756


2016 (Eighteen publications)

Fraietta JA, Melenhorst JJ, and Levine BL. 2016. Cell intrinsic PD-1 checkpoint blockade releases the brake on human chimeric antigen receptor (CAR) T cells for solid tumors. Translational Cancer Research, Vol 5, Supplement 7 (December 2016):


Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, and Schuster SJ. 2016. PD-1 Blockade Modulates Chimeric Antigen Receptor (CAR) Modified T Cells and Induces Tumor Regression: Refueling the CAR. Blood, December 28th. pii: blood-2016-09-738245.


Portnow J, Synold TW, Badie B, Tirughana R, Lacey SF, D'Apuzzo M, Metz MZ, Najbauer J, Bedell V, Vo T, Gutova M, Frankel P, Chen MY, and Aboody KS. 2016. Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients. Clinical Cancer Research, December 15th.


Rubin CB, Elenitsas R, Taylor L, Lacey SF, Kulikovskaya I, Gupta M, Melenhorst JJ, Loren A, Frey N, June CH, Porter D, and Rosenbach M. 2016. Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. Journal of the American Academy of Dermatology, November. 75(5) 1054-1057.


Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, and Gill S. 2016. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia, October 14th.


Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, and Teachey DT. 2016. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Critical Care Medicine, September 14th.


Brooks S, Frey N, Porter D, June C, Lacey S, Bagg A. 2016. The cytological features of CAR(T) cells. British Journal of Hematology, September 9th.


Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, and Gill S. 2016. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. Journal of Clinical Investigation, August 29th.


Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, Obstfeld AE, Lacey SF, Melenhorst JJ, Nazimuddin F, Hwang WT, Maude SL, Wasik MA, Bagg A, Schuster S, Feldman MD, Porter DL, Grupp SA, June CH, and Milone MC. 2016. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy. Blood, May 10.


Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, and Grupp SA. 2016. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discovery, Apr 13.


Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, Grupp SA, June CH, Melenhorst JJ, and Lacey SF. 2016. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. Journal of Immunological Methods, Apr 2.


Fraietta JA, Schwab RD, and Maus MV. 2016.Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Seminars in Oncology, Apr;43(2):291-9.

http://dx.doi.org/doi: 10.1053/j.seminoncol.2016.02.006

Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, and Beatty GL. 2016. IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. Cancer Discovery, Apr;6(4):400-13.


Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder N, Blair I, Milone MC, and June CH. 2016. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity, Feb 16th 44(2):380-390.


Carey AJ, Gracias DT, Thayer JL, Boesteanu AC, Kumova OK, Mueller YM, Hope JL, Fraietta JA, van Zessen DB, Katsikis PD 2016. Rapid Evolution of the CD8+ TCR Repertoire in Neonatal Mice. Journal of Immunology, Mar 15;196(6):2602-13.


Gracias DT, Boesteanu AC, Fraietta JA, Hope JL, Carey AJ, Mueller YM, Kawalekar OU, Fike AJ, June CH, Katsikis PD. 2016. Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections. Journal of Immunology, Feb 1;196(3):1186-98.


Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA. 2016. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research, Jun 1;22(11):2684-96.


Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, and Maus MV. 2016. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, Jan 26. pii: blood-2015-11-679134.


2015 (Eleven publications)

Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD Jr, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, and Maus MV. 2015. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for a Phase I trial in glioblastoma. Science Translational Medicine, 7(275).


Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, and Thomas-Tikhonenko A. 2015. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery 2015 Published OnlineFirst October 29, 2015; DOI: 10.1158/2159-8290.CD-15-1020 http://cancerdiscovery.aacrjournals.org/content/early/2015/10/30/2159-8290.CD-15-1020.full.pdf

Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, and Stadtmauer EA. 2015. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. New England Journal of Medicine Sept 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542. http://www.nejm.org/doi/full/10.1056/NEJMoa1504542

Melenhorst JJ, Lacey SF, and Bedoya F. 2015. Chimeric antigen receptor T cells: Self-replicating drugs for cancer. Current Drug Targets. Aug 25th . http://benthamscience.com/journals/current-drug-targets/article/134313/

Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, and June CH. 2015. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine. Sept 2nd 7(303)ra139. doi: 10.1126/scitranslmed.aac5415. http://stm.sciencemag.org/content/7/303/303ra139.full

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH. 2015. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine. Aug; 21(8):914-21. doi: 10.1038/nm.3910. Epub 2015 July 20th. http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.3910.html

Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop HE, Rooney CM, Shpall EJ, Barrett AJ, Rodgers JR, and Bollard CM. 2015. CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. Science Translational Medicine. 29 April 10. 7(285) p.285ra63


Pulsipher MA, Carlson C, Langholz B, Wall DA, Schultz KR, Bunin N, Kirsch I, Gastier-Foster JM, Borowitz M, Desmarais C, Williamson D, Kalos M, and Grupp SA. 2015. IgH-V(D)J NGS-MRD measurement pre- and early post- allo-transplant defines very low and very high risk ALL patients. Blood. April 10. pii: blood-2014-12-615757. [Epub ahead of print].


Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, and June CH. 2015. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunology Research. Apr;3(4):356-67. Epub 2015 Jan 19.


Weissler, KA, Garcia V, Kropf E, Aitken M, Bedoya F, Wolf AI, Erikson J, and Caton AJ. 2015. Distinct Modes of Antigen Presentation Promote the Formation, Differentiation, and Activity of Foxp3+ Regulatory T Cells In Vivo. Journal of Immunology. Mar 16. pii: 1402960. [Epub ahead of print].


Roederer M, Quaye L, Mangino M, Beddall MH, Mahnke Y, Chattopadhyay P, Tosi I, Napolitano L, Terranova Barberio M, Menni C, Villanova F, Di Meglio P, and Nestle FO. 2015. The Genetic Architecture of the Human Immune System: A Bioresource for Autoimmunity and Disease Pathogenesis. Cell. 161 1-17 April 9th.



Maus, MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, and June CH. Adoptive immunotherapy for cancer or viruses. 2014. Annual Review of Immunology, 32: 189-225.


Garfall, AL, Fraietta JA, and Maus MV. Immunotherapy with chimeric antigen receptors for multiple myeloma. 2014. Discovery Medicine, 91: 37-46.


Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, and Grupp SA. 2014. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. New England Journal of Medicine. Oct 16; 371(16):1507-1517.


Kenderian SS, Ruella M, Gill S, and Kalos M. 2014. Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Research. Nov 15;74(22):6383-9.


Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, and Vonderheide RH. 2014. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunology Research. Nov;2(11):1051-8.


Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin J, Leen AM, Heslop HE, Barrett AJ, Rooney CM, Bollard CM. 2014. Graft versus Leukemia Response without Graft versus Host Disease elicited by Adoptively Transferred Multivirus-specific T-cells. Molecular Therapy. Sep 30.


Ito S, Bollard CM, Carlsten M, Melenhorst JJ, Biancotto A, Wang E, Chen J, Kotliarov Y, Cheung F, Xie Z, Marincola F, Tanimoto K, Battiwalla M, Olnes MJ, Perl S, Schum P, Hughes TE, Keyvanfar K, Hensel N, Muranski P, Young NS, and Barrett AJ. 2014. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. American Journal of Molecular Therapy. Jul;22(7):1388-95.


Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, and Kalos M. 2014. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. Apr 10;123(15):2343-54.


Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, and June CH. 2014. Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. New England Journal of Medicine. 370: 901-910.


Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, and June CH. 2014. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies. Cancer Immunology Research. Feb 1; 2(2) 112-120.


Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, and June CH. 2014. Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells. Clinical Cancer Research. Mar 1;20(5):1355-65.


Kennedy-Nasser A, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, Savoldo B, Yvon E, Carrum G, Ramos CA, Krance R, Leung K, Heslop HE, Brenner MK, and Bollard CM. 2014. Ultra Low-Dose IL-2 for GVHD prophylaxis after Allogeneic HSCT mediates Expansion of Regulatory T Cells Without Diminishing Anti-viral and Anti-leukemic Activity. Clinical Cancer Research. Feb 26. [Epub ahead of print] http://dx.doi.org/10.1158/1078-0432.CCR-13-3205

Nakamura R, La Rosa C, Tsai W, Lacey SF, Srivastava T, Seidel A, Senitzer D, Forman SJ, and Diamond DJ. 2014. Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients. Transplant Immunology. May; 30(4) 128-35 Epub February 26th2014. http://dx.doi.org/10.1016/j.trim.2014.02.001

Tanimoto K, Muranski P, Miner S, Fujiwara H, Kajigaya S, Keyvanfar K, Hensel N, Barrett AJ, Melenhorst JJ. 2014. Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells. Cytotherapy. 16(1):135-46.

http://dx.doi.org/doi: 10.1016/j.jcyt.2013.08.008.

Ruella M and Kalos M. 2014. Adoptive immunotherapy for cancer. Immunological Reviews.

Article first published online: 13 Dec 2013 257: 14–38. http://dx.doi.org/10.1111/imr.12136



Metz MZ, Gutova M, Lacey SF, Abramyants Y, Vo T, Gilchrist M, Tirughana R, Ghoda LY, Barish ME, Brown CE, Najbauer J, Potter PM, Portnow J, Synold TW, Aboody KS. 2013. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cells Translational Medicine. 2(12): 983-92.


Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR, Shpall EJ, Melenhorst JJ, Leen AM, Barrett AJ, and Bollard CM. 2013. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia. Jul;27(7):1538-47.


Bedoya F, Cheng GS, Leibow A, Zakhary N, Weissler K, Garcia V, Aitken M, Kropf E, Garlick DS, Wherry EJ, Erikson J, Caton AJ. 2013. Viral antigen induces differentiation of Foxp3+ natural regulatory T cells in influenza virus-infected mice. Journal of Immunology. Jun 15;190(12):6115-25.


McIver Z, Melenhorst JJ, Wu C, Grim A, Ito S, Cho I, Hensel N, Battiwalla M, Barrett AJ. 2013 Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant. Haematologica. Mar; 98(3):346-52.


Melenhorst JJ, and Levine BL. 2013. Innovation and opportunity for chimeric antigen receptor targeted T cells. Cytotherapy. 15(9):1046-53.


Mahnke YD, Brodie TM, Sallusto F, Roederer M, and Lugli E. 2013. The who's who of T-cell differentiation: Human memory T-cell subsets. European Journal of Immunology. 43(11):2797-909.


Garfall AL, Kalos M, Furth EE, Vogl D, Weiss B, Cantor J, Gupta M, Levine B, Rapoport A, Ribeiro L, Jakobsen B, Smethurts D, Binder-Scholl G, June CH, and Stadtmauer EA. 2013. Autologous aGVHD Associated with Infusion of T-Cells with Engineered Specificity for NY-ESO-1 and LAGE-1 Following High-Dose Melphalan and ASCT in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation. 19 (2) Supplement Feb 2013 S134.


Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, Pumphrey NJ, Williams DD, Binder-Scholl G, Kulikovskaya I, Levine BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, and Jakobsen BK. 2013. Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells. Science Translational Medicine. August 7th, 5(197): 197ra103.


Kalos M and June CH. 2013. Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology. Immunity. July 25th. 39 (1): 49-60.


Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ, Mick R, Smith L, Coukos G. 2013. A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clinical Cancer Research. 19 (17): 1-15.


Gill S, and Porter D. 2013. Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effect. Annual Review of Medicine 64: 101-117.


Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, and June CH. 2013. Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood. August 8th; 122 (6): 863-871.


Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M and June CH. 2013. T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans. Cancer Immunology Research. 1 (1): 26-31.


Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, and Grupp SA. 2013. Cytokine Release Syndrome after Blinatunomab Treatment Related to Abnormal Macrophage Activation and Ameliorated with Cytokine Directed Therapy. Blood. June 27th. 121 (26): 5154-5157.


Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, and June CH. 2013. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine. April 18th. 368: 1509-1518.


Ascierto PA, Kalos M, Schaer DA, Callahan MK, and Wolchok JD. 2013. Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. Clinical Cancer Research. March 1st; 19(5):1009-1020.


Lacey SF, and Kalos M. 2013. Biomarkers in T-cell therapy clinical trials. Cytotherapy. June. 15 (6): 632-640.


McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, June CH, Kalos M, Ashfield R, and Jakobsen BK. 2013. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunology, Immunotherapy. April. 62 (4):773-785. http://dx.doi.org/10.1007/s00262-012-1384-4

Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, Humeau L. Kalos M, Papasavvas E, Montaner LJ, Schullery D, Shaheen F, Brennan AL, Zheng Z, Cotte J, Slepushkin V, Veloso E, Mackley A, Hwang W-T, Aberra F, Zhan J, Boyer J, Collman RG, Bushman FD, Levine BL, and June CH. 2013. Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long anti-sense to HIV. Blood. Feb 28; 121(9):1524-33.

doi: 1182/blood-2012-07-447250


Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, and Davis MM. 2012. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 37:1-2. http://dx.doi.org/10.1016/j.immuni.2012.07.010

Gill S, and Kalos M. 2012. T cell-based gene therapy of cancer. Translational Research : The Journal of Laboratory and Clinical Medicine. April; 161(4):365-79. http://dx.doi.org/10.1016/j.trsl.2012.11.002

Kalos M. 2012. Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses. Cancer Immunology, Immunotherapy : CII 61:127-135. http://dx.doi.org/10.1007/s00262-011-1173-5

Kandalaft LE, Kalos M, Melief CJ, Speiser DE, and Coukos G. 2012. Conference scene: Immune signatures in the tumor and beyond. Immunotherapy 4:761-772. http://dx.doi.org/10.2217/imt.12.70

Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, Li Y, Cameron BJ, Sami M, Baston EE, Todorov PT, Paston SJ, Dennis RE, Harper JV, Dunn SM, Ashfield R, Johnson A, McGrath Y, Plesa G, June CH, Kalos M, Price DA, Vuidepot A, Williams DD, Sutton DH, and Jakobsen BK. 2012. Monoclonal TCR-redirected tumor cell killing. Nature Medicine 18:980-987. http://dx.doi.org/10.1038/nm.2764

Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, and June CH. 2012. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science Translational Medicine. May 2nd. 4 (132): 132ra153. http://dx.doi.org/10.1126/scitranslmed.3003761

Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ Jr, Rao M, Restifo NP, Rosenberg SA, O'Shea J, and Melief CJ. New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. Journal of Translational Medicine 10:48. http://dx.doi.org/10.1186/1479-5876-10-48

Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM, June CH, and Zhang PJ. 2012. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Research and Treatment 133:799-804. http://dx.doi.org/10.1007/s10549-012-2018-4


Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM and the CRI-CIC Assay Working Group. 2011. A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. Journal of Translational Medicine. 9:108. http://dx.doi.org/10.1186/1479-5876-9-108

Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, and Grupp SA. 2011. Treatment of advanced leukemia in mice with mRNA engineered T cells. Human Gene Therapy 22:1575-1586. http://dx.doi.org/doi:10.1089/hum.2011.070

Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, and Davis MM. 2011. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunology, Immunotherapy: CII 60:15-22. http://dx.doi.org/10.1007/s00262-010-0940-z

Kalos M. 2011. Biomarkers in T cell therapy clinical trials. Journal of Translational Medicine 9:138. http://dx.doi.org/doi:10.1186/1479-5876-9-138

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, and June CH. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine 3:95ra73. http://dx.doi.org/10.1126/scitranslmed.3002842

Porter DL, Kalos M, Zheng Z, Levine B, and June C. 2011. Chimeric Antigen Receptor Therapy for B-cell Malignancies. Journal of Cancer 2:331-332. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119397/pdf/jcav02p0331.pdf

Porter DL, Levine BL, Kalos M, Bagg A, and June CH. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine 365:725-733. http://dx.doi.org/10.1056/NEJMoa1103849

Van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, and Hoos A. 2011. Harmonization of immune biomarker assays for clinical studies. Science Translational Medicine 3:108ps144. http://dx.doi.org/10.1126/scitranslmed.3002785


Cao LF, Krymskaya L, Tran V, Mi S, Jensen MC, Blanchard S, and Kalos M. 2010. Development and application of a multiplexable flow cytometry-based assay to quantify cell-mediated cytolysis. Cytometry. Part A : The Journal of the International Society for Analytical Cytology 77:534-545. http://dx.doi.org/doi:10.1002/cyto.a.20887

DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li M, Couture L, Hsu D, Forman SJ, Rossi JJ, and Zaia JA. 2010. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Science Translational Medicine 2:36ra43. http://dx.doi.org/10.1126/scitranslmed.3000931

Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, and Forman SJ. 2010. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 16:1245-1256.

Kalos M. 2010. An integrative paradigm to impart quality to correlative science. Journal of Translational Medicine 8:26. http://dx.doi.org/10.1186/1479-5876-8-26

Kalos M. 2010. HSP110 improves the anti-tumor effects of the cytotoxic T lymphocyte epitope E749-57 in mice: HSP110 as a peptide specific chaperone or adjuvant? Cancer Biology & Therapy 9. http://dx.doi.org/10.4161/cbt.9.4.11335


Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P, and the HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group. 2009. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunology, Immunotherapy: CII 58:1701-1713.


Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, and Davis MM 2009. "MIATA"-minimal information about T cell assays. Immunity 31:527-528. http://dx.doi.org/10.1016/j.immuni.2009.09.007

Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A, and the Elispot Proficiency Panel of the CVC Immune Assay Working Group. 2008. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunology, Immunotherapy: CII 57:303-315. http://dx.doi.org/10.1007/s00262-007-0380-6